Project Grant R01CA293595
Award Date 8/18/25
Completion Date 7/31/30
Dollars Obligated $657K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This federal Project Grant award, valued at $666,670.00, was provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research program) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The goal of this 4-year project, starting on January 15, 2025, is to develop improved quantification methods in oncology imaging by: Implementing an ultra-high-pitch spectral CT protocol to generate dynamic...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania provides $227,906 to conduct research on the immunomodulatory effects of the FDA-approved drug Photofrin and other heme oxygenase (HO)-1 inducing agents for the treatment of malignant pleural mesothelioma (MPM). The research aims to 1) characterize the tumor control and antitumor immunity generated by Photofrin and other HO-1 inducing drugs,...
- The National Cancer Institute (NCI) awarded a 5-year, $597,766 Project Grant to the University of Pennsylvania under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop novel methods for conducting dual-tracer positron emission tomography (PET) imaging in a single imaging session. The project aims to enable the concurrent use of multiple PET tracers to better characterize cancer, which could transform diagnostic capabilities and patient convenience compared to current...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $225,229 Project Grant to Navigation Sciences Inc., a small business located in Brookline, MA. This grant will fund the development of the EndonaviSCI software system, which aims to address two critical challenges in translating the NaviSCI real-time surgical navigation technology to the clinic: 1) ensuring accurate localization and placement of the J-Bar marker next to lung nodules without...
- The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $451,131 Project Grant to the University of Dayton Research Institute. The grant's objective is to generate endoplasmic reticulum (ER)-targeting fluorescent imaging agents to characterize the role of ER stress in non-small cell lung cancer (NSCLC) and develop directed cancer therapeutics based on observed responses. The project, led by Shawn Swavey and Kristen Krupa, aims...
- This Project Grant award of $400,000 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) is supporting the development of a novel, liver-specific positron emission tomography (PET) tracer. The goal is to enable more sensitive detection of metastatic liver tumors compared to current imaging modalities. The award, which runs from September 2025 to August 2026, will fund the completion of preclinical testing and Investigational New Drug...
- This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the University of Missouri System (UEI: SZPJL5ZRCLF4) to evaluate the effectiveness of an oncolytic adenovirus, OADSA-4-1BBL, alone or in combination with anti-PD-1 blockade, in an immunocompetent orthotopic lung cancer mouse model. The goal is to develop a novel oncolytic adenovirus that preferentially infects and kills lung cancer cells by targeting the...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $2,491,138 to Oregon Health & Science University (OHSU) to develop a fluorescence-guided nerve-sparing technique for colorectal cancer surgery. The project aims to enable real-time visualization of nerves during surgery using a novel near-infrared fluorescent contrast agent, with the goal of improving surgical outcomes and reducing post-operative morbidity such as...
- This federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of a novel polyphosphazene nanoparticle (PPNP) platform for enhanced treatment of breast cancer. The $391,826 award, granted on July 16, 2025, will fund research conducted by the University of Pennsylvania to create a PPNP loaded with ultrasmall silver sulfide nanoparticles. This platform aims to improve photothermal therapy and deliver a...